Outcomes of Patients Underrepresented in Pivotal Trials of Anti-CD19 CAR-T Cell Therapy

Three commercial anti-CD19 chimeric antigen receptor modified T-cell therapies (CAR-T) were approved for the treatment of chemo-refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) based on results from pivotal registration trials that had strict inclusion and exclusion criteria. Additionally, despite enrollment across multiple large centers, underrepresented minorities (URMs) accounted for a small portion of the trial participants (e.g., only 11% enrolled to ZUMA1 were non-White).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 246 Source Type: research